Dr. Lars Hedbys is a member of the Ventac Partners team since 2006. He has over 30 years of life science industry and science experience including over 20 years in senior and executive management positions.
Dr. Hedbys is co-founder and CEO of Idogen AB, a publicly traded company listed on AktieTorget in Stockholm. Idogen is an innovative company with the aim of introducing the first tolerogenic vaccine. Lars Hedbys is also serving as Chairman of the Board of Lund Life Science Incubator. This is a not for profit company dedicated to providing business development support and state of the art laboratory facilities to life science start-up companies. Dr. Hedbys is also co-founder of Regenesance BV (The Netherlands) and Casigen Pharma Ltd (Hong Kong).
Lars Hedbys contributes with an extensive experience in drug development, product strategy development and business development. He has a track record of leading large operational organizations, organizations in change as well as building and growing young life science companies. His curriculum includes a number of board membership roles.
Important positions in Dr. Hedbys’ curriculum include: CEO of Glycorex Transplantation AB (listed on the NGM stock exchange), CEO of AB Mando, General Manager of Synarc A/S, Vice President and Site General Manager of AstraZeneca R&D Lund and Vice President, Global Clinical Operations & Project Management of AstraZeneca R&D.
Dr Hedbys holds a MSc in chemical engineering from Chalmers University of Technology and a PhD in Applied Biochemistry from the University of Lund.